Research programme: BACE1 protein inhibitors - Vitae Pharmaceuticals/Boehringer IngelheimAlternative Names: BACE1 inhibitors - Vitae; Beta secretase inhibitors - Vitae; BI 1147560; VTP 36951
Latest Information Update: 02 Aug 2015
At a glance
- Originator Vitae Pharmaceuticals
- Developer Boehringer Ingelheim; Vitae Pharmaceuticals
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease